HLA Typing for Transplant Companies

The global human leukocyte antigen (HLA) typing for transplant market is projected to reach USD 1.4 billion by 2030 from USD 1.1 billion in 2025, at a CAGR of 6.0% during the forecast period. The notable year-on-year increase in organ transplant procedures is primarily attributable to lifestyle factors such as sedentary behavior, poor dietary choices, obesity, diabetes, and hypertension, which have accelerated the prevalence of chronic kidney and liver diseases. These trends are particularly pronounced in the aging demographic, resulting in a heightened demand for organ transplants. Concurrently, an aging workforce coupled with the rising incidence of cardiovascular diseases has intensified the need for heart transplants. These dynamics have collectively contributed to an upward trajectory in transplant volumes, which is projected to escalate demand for high-throughput and precision HLA testing.

Over the past five years, the total number of organ transplants has risen by approximately 23.3% compared to the previous period, indicating a significant escalation in transplant procedures. This upward trend in organ transplant volume is anticipated to drive hospitals and transplant laboratories to adopt rapid and high-throughput methods for accurate HLA typing. Furthermore, the progression of xenotransplantation is expected to gain broader acceptance, fueled by advancements in cross-species immunogenetics and innovative HLA mapping techniques. Such developments are likely to catalyze research into synthetic HLA typing models. The increasing demand for organ transplants correlates closely with lifestyle and occupational determinants. Sedentary lifestyles, poor dietary choices, obesity, diabetes, and hypertension contribute to a rise in chronic kidney and liver pathologies. The consumption of alcohol and tobacco is linked to liver cirrhosis and COPD, thereby escalating the requirement for liver and lung transplants. Additionally, occupational exposure to industrial pollutants, particularly within mining and manufacturing sectors, has been shown to cause significant lung and liver damage. Compounded by an aging workforce and a rise in cardiovascular disease incidence, there is a growing need for heart transplants. These factors underscore the critical role of HLA typing in ensuring donor-recipient compatibility, which is essential for optimizing transplant outcomes.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), QIAGEN (Germany), CareDx (US), F. Hoffmann-La Roche Ltd. (Switzerland), Immucor, Inc. (US),  Werfen (US), TBG Biotechnology Corporation (Taiwan), Fujirebio (Japan), Omixon Inc. (US), GenDx (Netherlands), BAG Diagnostics GmbH (Germany), Creative Biolabs (US), PacBio (US) are some of the prominent pleayers in HLA typing for transplant market.

Thermo Fisher Scientific (US) is a preeminent entity in the domain of HLA typing for transplant applications, driven by strategic investments and a robust growth trajectory in this sector. The company provides extensive offerings encompassing PCR-based assays, advanced sequencing technologies, and comprehensive software solutions tailored for HLA typing. This diverse product portfolio meets the varied requirements of transplant centers and laboratories, ensuring optimized workflows and enhanced accuracy. To maintain its competitive edge, Thermo Fisher prioritizes R&D, continually advancing its HLA typing technologies; this unwavering commitment to innovation enhances its product capabilities and positions it at the forefront of the industry, delivering cutting-edge solutions that address the evolving needs of the transplant immunology landscape.

QIAGEN (Germany) provides extensive products and solutions tailored for HLA typing, encompassing PCR-based assays, next-generation sequencing (NGS) platforms, and associated reagents. This robust product portfolio positions QIAGEN to effectively meet the varied demands of transplant centers and clinical laboratories. QIAGEN's NGS-based offerings, such as the QIAseq HLA Typing Panel, invest significantly in developing cutting-edge technologies for HLA typing and delivering high-resolution and precise HLA typing results. These advancements enhance transplant matching efficacy and overall patient outcomes. With a strong global market presence, QIAGEN leverages a comprehensive network of distribution channels and strategic partnerships across multiple regions, enabling it to serve a diverse clientele of transplant centers and laboratories worldwide. Strategic acquisitions and collaborations have fortified QIAGEN's standing in the market. Notably, the acquisition of N-of-One, Inc. has expanded its capabilities in precision medicine and clinical decision support, with significant implications for transplantation applications. Additionally, QIAGEN offers customizable products that accommodate the specific requirements of individual laboratories and transplant centers, providing flexibility that appeals to a broad spectrum of customers. The company frequently collaborates with research institutions and organizations engaged in transplantation research, further reinforcing its commitment to advancing the field.

Illumina, Inc. (US) is a leading entity in genomics, particularly noted for its advancements in HLA typing for transplantation. Its DNA sequencing platforms, including the HiSeq and NovaSeq systems, are implemented in HLA typing protocols due to their high throughput, precision, and scalability, which are crucial for extensive HLA typing endeavors. As a pioneer in next-generation sequencing (NGS) technology, Illumina has significantly transformed HLA typing methodologies, enabling high-resolution typing that enhances donor-recipient matching and, subsequently, transplant success rates. The company has engaged in strategic collaborations with various organizations within transplantation research and diagnostics, fostering innovation and broadening the scope of its sequencing technologies. Continuous R&D investments have been a hallmark of Illumina's operation, focusing on creating specialized assays and workflows tailored specifically for HLA typing and transplantation research applications. Illumina’s sequencing technologies are employed in research and clinical laboratories globally, allowing the company to support transplant centers, hospitals, and research institutions worldwide, which has propelled its expansion in the HLA typing sector. Furthermore, Illumina provides an array of bioinformatics tools and software that help analyze and interpret HLA data, extracting meaningful insights from the extensive datasets generated during HLA typing procedures.

Market Ranking

The global HLA typing market for transplant applications is highly consolidated, featuring a dominant quintet of major players—Thermo Fisher Scientific Inc., Illumina, QIAGEN, F. Hoffmann-La Roche Ltd., and Bio-Rad Laboratories—collectively commanding approximately 75% of market share. Thermo Fisher Scientific (US) stands out as the foremost leader in this sector, consistently launching innovative products to reinforce its competitive edge. The company has effectively bolstered its revenue trajectory and market presence through strategic acquisitions and expansions. Illumina, Inc. (US) is another formidable contender, recognized for its advanced technological offerings. Its product portfolio encompasses a wide array of interconnected solutions, including next-generation sequencing (NGS), genotyping assays, gene expression analysis, and molecular diagnostic tools. QIAGEN (Germany) maintains a significant foothold in the HLA typing for transplant domain, leveraging a comprehensive range of molecular diagnostics and analytics products. Over recent years, the company has strategically pursued growth through partnerships, collaborations, and new product introductions. F. Hoffmann-La Roche Ltd. (Switzerland) also holds a considerable share in the global HLA typing market for transplants. The remaining 25% of market share is distributed among various smaller, regional, or niche players, collectively catering to specialized segments within the industry.

Related Reports:

HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real-time), NGS, Sanger), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), Type (Organ, Soft Tissue), End User (Hospital, Clinic) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com